Application No.: 10/079,429 Docket No.: PF106P3D1

REMARKS

Status of the claims:

Claims 15-21 have been added. Support for new claims 15-21 can be found in specification as originally filed, for example in paragraphs [0017], [0079] – [0080] and in Examples 2, 4, and 7. Additional support may be found in the originally filed claims 3-5 and 17-20 of parent application serial number 08/465,679. The present application claims the benefit of priority of the 08/465,679 application and incorporates said application by reference. Thus, no new matter has been added.

Amendment of the Specification:

Paragraph [0001] of the specification has been amended to correct a typographical error. There was a transposition of two numbers in the recitation of the serial number of parent patent application serial number 08/465,679. The serial number of this application was correctly listed on the Initial Application Data Sheet filed on February 22, 2002. According to 37 C.F.R. § 1.76(b)(5), the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, 37 C.F.R. § 1.78(a) (2) or 37 C.F.R. § 1.78(a)(4) and no other claim to priority need be made in the specification. The present amendment is intended only to correct a typographical error in paragraph [0001] so that the information relayed in paragraph [0001] is in keeping with the priority claimed in the Application Data Sheet. Applicants respectfully request entry of this amendment.

Substitute Sequence Listing

The Substitute Sequence Listing submitted herewith has been amended to correct the priority information in the <150> line relating to parent application 08/465,679. The

Docket No.: PF106P3D1 Application No.: 10/079,429

same typographical described above was made on page one of the sequence listing.

Support for this amendment is in the Initial Application Data Sheet filed February 22,

2002.

Additionally Applicants have updated the <140> line to reflect Serial Number

accorded the present application.

Applicants respectfully request that the substitute sequence listing be entered and made

of record. Submitted herewith are Statements Under 37 C.F.R. § 1.825(a) and (b).

CONCLUSION

Applicants respectfully request that the amendments and remarks above be entered and

made of record in the file history of the instant application. Should any fees additional to those

listed on the Fee Transmittal Sheet be deemed necessary, please charge such fees to Deposit

Account No. 08-3425.

Dated: January 27, 2003

Respectfully submitted.

Registration No.: 43,975

Human Genome Sciences, Inc. 9410 Key West Avenue

Rockville, MD 20850

(301) 610-5772

6



Docket No.: PF106P3D1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	
Haseltine et al.	

Application No.: 10/079,429

Group Art Unit: 1646

Filed: February 22, 2002

Examiner: Not Yet Assigned

For: HUMAN DNA MISMATCH REPAIR

PROTEINS

CENTER 1600/2900

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Amendments were made to the application as follows. Amendments are shown in bold-faced text with deletions indicated by strikeout and insertions indicated by underlining.

In the specification

Paragraph [0001] has been replaced with the following amended paragraph.

[0001] This application is a divisional of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/468,024 filed June 6, 1995, which is a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, International Application No. PCT/US95/01035 filed January 25, 1995; U.S. Patent Application Serial No. 08/468,024 filed June 6, 1995 is also a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/294,312 filed August 23, 1994, which is a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/210,143 filed March 16, 1994, which is a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/187,757 filed January 27, 1994; and this application is also a divisional of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/465,679 08/465,769 filed June 6, 1995, which is a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/294,312 filed August 23, 1994, which is a continuation-in-part of, and claims the benefit

Application No.: 10/079,429 Docket No.: PF106P3D1

of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/210,143 filed March 16, 1994, which is a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/187,757 filed January 27, 1994; and this application is also a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/294,312 filed August 23, 1994, which is a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/210,143 filed March 16, 1994, which is a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/187,757 filed January 27, 1994; and this application is also a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/210.143 filed March 16, 1994, which is a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/187,757 filed January 27, 1994; and this application is also a continuation-in-part of, and claims the benefit of priority under 35 U.S.C. § 120 of, U.S. Patent Application Serial No. 08/187,757 filed January 27, 1994. Each of the aforementioned U.S. and International patent applications are hereby incorporated by reference in their entireties.

In the Sequence Listing

The originally filed sequence listing has been replaced by the substitute sequence listing submitted herewith.

In the Claims

Claims 15-21 were added.